Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda, Merck Serono Drop Matuzumab due to Inefficacy
March 3, 2008
- Real Medical Institution Bankruptcy Crisis Yet to Come
March 3, 2008
- PIII Trial of Nexavar in NSCLC Discontinued: Bayer, Onyx
March 3, 2008
- Negative Opinions Include Fear of Clinical Trials: CMIC
March 3, 2008
- TOPICS／Pfizer Foundation Supports 2 Japanese NGOs to Fight Tobacco and Breast Cancer
March 3, 2008
- Daiichi Sankyo Places Top Priority on 5 Projects
March 3, 2008
- Sanofi-aventis Enters into Antibody Agreements with Dyax
March 3, 2008
- Blood Pressure Management Not Adequate: Pfizer Survey
March 3, 2008
- Toyobo Expands Contract Manufacturing Business
March 3, 2008
- NCCHD-Led NW to Participate in Multinational Clinical Trials
March 3, 2008
- Sales of Plavix Up 5.5-Fold in Japan: sanofi-aventis
March 3, 2008
- Development Delayed for 16 Unapproved Drugs
March 3, 2008
- Competition Heats Up on the Market for Statins
March 3, 2008
- Introduce GCP Auditor Certification System: Prof. Horie
March 3, 2008
- Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
March 3, 2008
- Korosho to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells
March 3, 2008
- Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
March 3, 2008
- Daiichi Sankyo, Eli Lilly Apply for Prasugrel in EU
March 3, 2008
- Number of Privately-Operated Pharmacies to be Halved: Mr Urushibata
March 3, 2008
- New GL on Drugs Obtained from Autologous Cells Announced
March 3, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…